Earnings summaries and quarterly performance for MARIMED.
Executive leadership at MARIMED.
Board of directors at MARIMED.
Research analysts who have asked questions during MARIMED earnings calls.
Pablo Zuanic
Zuanic & Associates
6 questions for MRMD
Also covers: ACB, AFCG, CGC +14 more
AS
Andrew Semple
Echelon Capital Markets
3 questions for MRMD
Also covers: AAWH, AYRWF, HITI +6 more
JR
Jesse Redmond
Water Tower Research LLC
1 question for MRMD
Also covers: GLASF, HYFM, ROMJF
JG
Joe Gomes
Noble Capital Markets
1 question for MRMD
Also covers: ACCO, BLBX, BTBT +15 more
JG
Joseph Gomes
G.research, LLC
1 question for MRMD
Also covers: ACCO, BTBT, CMTL +17 more
WM
William McFarland
GDR Research
1 question for MRMD
WM
William McNarland
TDR Research
1 question for MRMD
Recent press releases and 8-K filings for MRMD.
MariMed CEO Comments on Cannabis Rescheduling
MRMD
Revenue Acceleration/Inflection
Accounting Changes
- MariMed's CEO, Jon Levine, stated on December 18, 2025, that the reclassification of cannabis as a Schedule III drug by the Trump Administration is the "single greatest cannabis reform in US history".
- This reclassification officially recognizes cannabis's widely accepted medical uses and low abuse potential.
- The change is expected to accelerate medical research and significantly increase consumer adoption of cannabis as an alternative to opioids.
- Crucially for businesses, state-legal cannabis operators like MariMed will no longer be subject to the IRS Section 280E tax penalty, which is projected to materially improve profitability and free cash flow.
Dec 18, 2025, 6:52 PM
MariMed Inc. Reports Q3 2025 Earnings and Strategic Expansion
MRMD
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- MariMed Inc. reported revenue of $40.8 million for Q3 2025, a slight increase from $40.6 million in Q3 2024, and a Non-GAAP Adjusted EBITDA of $5.1 million, up from $4.7 million in the prior year period. The company posted a GAAP net loss of $(2.9) million for Q3 2025.
- The company is expanding its brand distribution to new markets, including Maine, Pennsylvania, and New York, through licensing and managed services agreements, with distribution anticipated to begin in 2026 for Pennsylvania and New York.
- MariMed plans to launch hemp-derived THC products, with initial distribution expected in Rhode Island by early 2026, and has exited the Missouri market.
Nov 5, 2025, 10:04 PM
MariMed Reports Third Quarter 2025 Financial Results
MRMD
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- MariMed Inc. reported revenue of $40.8 million for the third quarter ended September 30, 2025, reflecting sequential growth.
- The company achieved Non-GAAP Adjusted EBITDA of $5.1 million for Q3 2025, representing a 13% margin, also a sequential increase.
- MariMed expanded brand distribution to Maine, Pennsylvania, and New York, launched adult-use sales in Delaware, and exited the Missouri market.
- The company plans to launch hemp-derived THC products, with anticipated distribution in Rhode Island by early 2026.
Nov 5, 2025, 10:00 PM
MariMed Announces Entry into Hemp-Derived THC Market
MRMD
Product Launch
New Projects/Investments
- MariMed Inc. has announced manufacturing and distribution agreements to launch hemp-derived THC versions of its top-selling beverage and edibles brands, and , as part of its Expand the Brand strategy.
- The first product, a hemp-derived THC version of the Vibations hydrating drink mix, is expected to be available in Rhode Island by early first quarter of 2026.
- To support this expansion, MariMed has partnered with DeHydr8 for advanced technology, Countermeasures for national sales and marketing, and Craft Collective Homegrown for distribution in Rhode Island.
- The company has established a new business unit, MMA Hemp Inc., to manage its hemp-derived THC activities.
Nov 3, 2025, 10:00 PM
MariMed Exits Missouri Market to Enhance Financial Performance
MRMD
New Projects/Investments
Guidance Update
- MariMed Inc. (MRMD) has announced its immediate exit from the Missouri market after completing a strategic review of its business operations there.
- The company had been managing Missouri operations and distributing its brands since 2024, while awaiting license transfer approval, but will no longer manage the facility or seek the transfer.
- This strategic exit is expected to improve MariMed's overall financial performance, particularly gross margin and adjusted EBITDA, by allowing management to focus resources on higher-return opportunities in its core markets.
- MariMed continues to own or manage revenue-generating operations in six states, including 13 dispensaries and six cultivation and processing facilities.
Oct 28, 2025, 9:00 PM
Quarterly earnings call transcripts for MARIMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more